



**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A method of ~~A pharmaceutical composition for improving~~ at least one symptom resulting from a tumor cell in a patient in need thereof, comprising administering to the patient a compound of ~~represented by the following general~~ formula (1) or a pharmacologically acceptable salt thereof: ~~as an active ingredient.~~





wherein  $R^1$  represents a hydrogen atom or a C2-4 alkanoyl group and  $R^2$  represents a group represented by the following ~~formulae~~ formula (A), (B), ~~(C)~~, (D), (E), (F) or (G):




wherein  $R^3$  represents a C1-4 alkyl group.

2. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, comprising improving at least one symptom by apoptosis of the tumor cell.
3. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, comprising improving at least one symptom resulting from the tumor cell without the contribution of apoptosis of the tumor cell.
4. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 3, comprising improving at least one symptom resulting from the tumor cell by inhibiting activation of NF- $\kappa$ B.








5. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 3, wherein the symptom is a tumor metastasis.
6. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 5, comprising improving the tumor metastasis by inhibiting adhesion to a vascular endothelial cell.
7. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, comprising improving at least one symptom resulting from the tumor cell by inhibiting proliferation of the tumor cell.
8. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, wherein the symptom is one selected from the group consisting of Hodgkin's disease, cancer cachexia, and leukemia.
9. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 3, wherein the tumor cell is a breast cancer cell.
10. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 3, wherein the composition is represented by the following formula (1a) or (1b):  
[[.]]



11. (Currently Amended) The method pharmaceutical composition of claim 8, comprising improving at least one symptom among loss of body weight, a decrease in hematocrit, a decrease in fat, and a decrease in muscle, which are the symptoms of cancer cachexia.
12. (Currently Amended) The method pharmaceutical composition of claim 3, comprising improving at least one symptom resulting from the tumor cell by inhibiting intratumoral angiogenesis formed by the tumor cell.
13. (Currently Amended) A method pharmaceutical composition comprising as an active ingredient a compound, represented by the following general formula (1), which is capable of enhancing the effect of a therapy by inhibiting activation of NF- $\kappa$ B caused by the therapy that causes the activation of NF- $\kappa$ B in a patient treated by the therapy, or a pharmacologically acceptable salt thereof, comprising administering to the patient a composition comprising a compound of formula (1) or a pharmacologically acceptable salt thereof:



wherein R<sup>1</sup> represents a hydrogen atom or a C2-4 alkanoyl group and R<sup>2</sup> represents a group represented by the following ~~formulae~~ formula (A), (B), (C), (D), (E), (F) or (G):



wherein R<sup>3</sup> represents a C1-4 alkyl group.



14. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 13, wherein the therapy that activates NF-κB is a therapy using an antitumor agent.

15. (Currently Amended) The ~~method pharmaceutical composition~~ of claim 13, wherein the therapy that activates NF-κB is radiotherapy for a tumor cell.


16. (Currently Amended) The ~~method pharmaceutical composition~~ of claim 14, comprising the antitumor agent as an active ingredient.

17. (Currently Amended) The ~~method pharmaceutical composition~~ of claim 14, wherein the antitumor agent is camptothecin or daunorubicin.


18. (Currently Amended) The ~~method pharmaceutical composition~~ of claim 13, wherein the compound is represented by the following formula (1a) or (1b):~~[[.]]~~



19. (Currently Amended) A ~~method of tumor cell proliferation inhibitor for~~ inhibiting proliferation of a tumor cell in a cancer patient comprising administering to the patient a compound of ~~represented by the following general formula (1) or a pharmacologically acceptable salt thereof as an active ingredient.~~





wherein R<sup>1</sup> represents a hydrogen atom or a C2-4 alkanoyl group and R<sup>2</sup> represents a group represented by the following formulae formula (A), (B), ~~(C)~~, (D), (E), (F) or (G):




wherein R<sup>3</sup> represents a C1-4 alkyl group.


20. (Currently Amended) The method ~~tumor cell proliferation inhibitor~~ of claim 3, wherein the composition is represented by the following formula (1a) or (1b):[[.]]



21. (Currently Amended) A method of ~~An adhesion molecule expression inhibitor for~~ suppressing the expression of an adhesion molecule in a vascular endothelial cell, comprising administering to the cell a compound of ~~represented by the following general~~ formula (1) or a pharmacologically acceptable salt thereof; ~~as an active ingredient.~~





wherein R<sup>1</sup> represents a hydrogen atom or a C2-4 alkanoyl group and R<sup>2</sup> represents a group represented by the following formulae (A), (B), (C), (D), (E), (F) or (G):




wherein R<sup>3</sup> represents a C1-4 alkyl group.







22. (Currently Amended) The method of claim 21~~adhesion molecule expression-inhibitor derived from a vascular endothelial cell~~, wherein the composition is the following formula (1a) or (1b):[[.]]



23. (Currently Amended) A method of An apoptosis inducer for inducing apoptosis of  
a tumor cell, comprising administering to the cell a compound of represented by the  
following general formula (1) or a pharmacologically acceptable salt thereof ~~as an active~~  
~~ingredient.~~





wherein R<sup>1</sup> represents a hydrogen atom or a C2-4 alkanoyl group and R<sup>2</sup>  
represents a group represented by the following ~~formulae~~ formula (A), (B), ~~(C)~~, (D), (E),  
(F) or (G):




wherein R<sup>3</sup> represents a C1-4 alkyl group.

24. (Currently Amended) The method of claim 23 ~~An apoptosis inducer~~, wherein the composition is represented by the following formula (1a) or (1b):[[.]]




25. (Currently Amended) A method of improving or inhibiting ~~Preventive and therapeutic agents for arteriosclerosis in a patient in need thereof~~, comprising administering to the patient a compound having NF- $\kappa$ B-inhibitory effect ~~as an active ingredient~~.

26. (Currently Amended) The method ~~preventive and therapeutic agents of claim 25~~, wherein the compound having NF- $\kappa$ B inhibitory effect is represented by the following ~~general-formula (1) or a pharmacologically acceptable salt thereof~~:[[.]]



wherein  $R^1$  represents a hydrogen atom or a C2-4 alkanoyl group and  $R^2$  represents a group represented by the following ~~formulae~~formula (A), (B), (C), (D), (E), (F) or (G):




wherein  $R^3$  represents a C1-4 alkyl group.








27-28. (Canceled)

29. (Currently Amended) ~~The preventive and therapeutic agents of claim 27, which~~  
~~is are used for~~ A method of preventing or inhibiting repressing cancer metastasis,  
comprising administering to a cancer patient a compound having NF- $\kappa$ B inhibitory effect.

30. (Currently Amended) A method of alleviating or inhibiting therapeutic agent for cachexia in a patient in need thereof, comprising administering to the patient a compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof as an active ingredient: [[.]]





wherein R<sup>1</sup> represents a hydrogen atom or a C2-4 alkanoyl group and R<sup>2</sup> represents a group represented by the following ~~formulae~~ formula (A), (B), (C), (D), (E), (F) or (G):



wherein R<sup>3</sup> represents a C1-4 alkyl group.

31. (Currently Amended) The ~~method therapeutic agent for cachexia~~ of claim 30, wherein the composition is represented by the following formula (1a) or (1b):[[.]]



32. (Currently Amended) The ~~method therapeutic agent for cachexia~~ of claim 30, wherein the patient is a cancer patient~~which is a therapeutic agent for cancer cachexia in a tumor patient.~~

33. (Currently Amended) The ~~method pharmaceutical composition~~ of claim 30, comprising improving at least one symptom among loss of body weight, a decrease in hematocrit, a decrease in fat, and a decrease in muscle, which are the symptoms of the cancer cachexia.

34. (Currently Amended) A method of alleviating or inhibiting ~~therapeutic agent for cachexia in a patient in need thereof~~, comprising administering to the patient a compound having NF- $\kappa$ B-inhibitory effect~~as an active ingredient~~.

35-46. (Canceled)